Our eyesight is essential to getting around, but if you’re not careful it can be seriously challenged by age-related macular ...

The global macular degeneration treatment market size was valued at USD 10.06 billion in 2024 and it is projected to reach ...

Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a ...

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

Macular degeneration is a leading cause of vision loss for people over 50, but there are ways to help protect your eyesight.

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...

Study from Case Western Reserve University and VA Northeast Ohio Healthcare System examines genetic risk profiles across ...

The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...

The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...

The eye's macula is impacted by macular degeneration, a neurodegenerative condition. Macular degeneration will cause loss of central vision because it gives the clear main idea required to see ...